Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance
Recruiting now · Phase 3
Conditions studied: Myeloproliferative Neoplasms (MPN)
In brief
Patients with myeloproliferative neoplasm (MPN) could have laboratory aspirin resistance and then increasing dose of aspirin from once daily to twice daily regimen is suggested. However, it is not routinely recommended to perform platelet function testing to determine aspirin resistance in MPN patients. Moreover, it is not known whether increasing dose of aspirin would always correct aspirin resistance and significantly prevent the thrombotic events in MPN patients. Therefore, this study aims to compare the efficacy of once daily versus twice daily aspirin in high-risk MPN patients with aspirin resistance. MPN patients with laboratory aspirin resistance will be included in this prospective randomized study and platelet function testing will be repeated at one and six months later. Clinical thrombosis and side effect from aspirin will be recorded for at least 2 years after intervention.
Key facts
- Study ID
- NCT06740916
- Run by
- Siriraj Hospital
- People needed
- 240
- Starts
- 2024-12-12
- Expected to finish
- 2030-12-31
- Last updated by the study team
- 2024-12-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Philadelphia negative Myeloproliferative neoplasms aged at least 18 years old
You may not qualify if…
- Concomitant other active malignancy or cured less than 6 months
- Platelet count less than 50,000/microL
- Receiving anticoagulant
- Active peptic ulcer
- Active bleeding or Planning to undergo procedure/operation with bleeding risk
- No laboratory aspirin resistance with LTA method
Where it is running
- Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital — Bangkok Noi, Bangkok, Thailand (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.